中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎病毒HLA-A2限制性复合多表位基因重组腺病毒的包装、筛选及鉴定

韦三华 任继鸿 刘丽 贾战生 董轲 林芳 王希 张利军 刘昕阳 张惠中

韦三华, 任继鸿, 刘丽, 贾战生, 董轲, 林芳, 王希, 张利军, 刘昕阳, 张惠中. 丙型肝炎病毒HLA-A2限制性复合多表位基因重组腺病毒的包装、筛选及鉴定[J]. 临床肝胆病杂志, 2011, 27(1): 53-56.
引用本文: 韦三华, 任继鸿, 刘丽, 贾战生, 董轲, 林芳, 王希, 张利军, 刘昕阳, 张惠中. 丙型肝炎病毒HLA-A2限制性复合多表位基因重组腺病毒的包装、筛选及鉴定[J]. 临床肝胆病杂志, 2011, 27(1): 53-56.
Wei SanHua, Ren JiHong, Liu Li, Jia ZhanSheng, Dong Ke, Lin Fang, Wang Xi, Zhang LiJun, Liu XinYang, Zhang HuiZhong. Packaging, selection and identification of recombinant adenoviruses carrying HCV HLA-A2 restricted compound multi-epitopes antigen[J]. J Clin Hepatol, 2011, 27(1): 53-56.
Citation: Wei SanHua, Ren JiHong, Liu Li, Jia ZhanSheng, Dong Ke, Lin Fang, Wang Xi, Zhang LiJun, Liu XinYang, Zhang HuiZhong. Packaging, selection and identification of recombinant adenoviruses carrying HCV HLA-A2 restricted compound multi-epitopes antigen[J]. J Clin Hepatol, 2011, 27(1): 53-56.

丙型肝炎病毒HLA-A2限制性复合多表位基因重组腺病毒的包装、筛选及鉴定

详细信息
  • 中图分类号: R392

Packaging, selection and identification of recombinant adenoviruses carrying HCV HLA-A2 restricted compound multi-epitopes antigen

  • 摘要:

    目的构建丙型肝炎病毒(HCV)HLA-A2限制性复合多表位基因的重组转移质粒pAdtrack-CMV-Ub-Mep,转染HEK293细胞,包装重组腺病毒rAd-Ub-Mep。方法复合表位Ub-Mep基因克隆到pAdTrack-CMV穿梭质粒,得到重组的穿梭质粒pAdtrack-CMV-Ub-Mep,将穿梭质粒pAdtrack-CMV-Ub-Mep和腺病毒骨架质粒pAdEasy1共转染HEK293细胞,产生重组腺病毒rAd-Ub-Mep,通过检测绿色荧光蛋白(GFP)的表达和PCR扩增目的基因的方法鉴定重组腺病毒,并测定重组腺病毒滴度。结果经酶切鉴定、PCR鉴定和荧光分析,均证实得到重组的腺病毒。测定病毒滴度为1.2×1011cfu/L。结论成功包装出重组腺病毒rAd-Ub-Mep,构建了HCV HLA-A2限制性多表位基因的重组腺病毒疫苗,为进一步研究HLA-A2限制性复合多表位基因诱导的细胞免疫应答奠定了基础。

     

  • [1]韦三华, 尹文, 雷迎峰, 等.HCV多表位基因重组BCG的筛选及其诱导的免疫应答研究[J].中华微生物学和免疫学杂志, 2007, 27 (11) :1041-1045.
    [2]Wei SH, Yin W, An QX, et al.A novel HCV vaccine approach using recombinant BCG expressing multi-epitope antigen[J].Archieve of viology, 2008, 153 (6) :1021-1029.
    [3]韦三华, 董轲, 林芳, 等.HCV HLA-A2限制性复合多表位基因的构建、克隆表达及其免疫特性分析[J].中国免疫学杂志, 2001, 33 (1) :73-75.
    [4]Houshton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436 (7053) :961-966.
    [5]Kawai T, Akira S.Innate immune recognition of viral infection[J].Nat Immunol, 2006, 7 (2) :131-137.
    [6]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.
    [7]Form X, Bukh J, Purcell R H.The challenge of developing a vaccine against hepatitis C virus[J].J Hepatol, 2002, 37 (5) :684-695.
    [8]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.
    [9]Ward S, Lauer G, Isba R, et al.Cellular immune responses against hepatitis C virus:the evidence base 2002[J].Clin Exp Immunol, 2002, 128 (2) :195-203.
    [10]Yu H, Huang H, Xiang J, et al.Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3[J].J Gen Virol, 2006, 87 (Pt1) :1-10.
    [11]Arribillaga L, de Cerio AL, Sarobe P, et al.Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus[J].Vaccine, 2002, (21) :202-210.
    [12]Hao CQ, Li Gy, Zhou YX, et al.Construction, package and identification of replication-deficient recombinant adenovirus expression vector of HCV C[J].World Chin J Digestol, 2003, 11 (2) :144-147.
  • 加载中
计量
  • 文章访问数:  3609
  • HTML全文浏览量:  11
  • PDF下载量:  823
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回